ENCALS PROGRAM
Oxford 20th-22nd June 2018

WEDNESDAY 20TH JUNE

12.00-13.15   Lunch and Registration
13.15-13.30   Welcome
13.30-14.00   Roadmaps to therapy in ALS
               Matthew Kiernan, Sydney
14.00-15.30   Biophysical basis of the acute effects of riluzole and retigabine on
               motor axonal excitability in patients with ALS
               Boudewijn Sleutjes, Utrecht 3005

               Connectome-based disease progression model for amyotrophic lateral
               Sclerosis
               Jil Meier, Utrecht 3014

               CSF chitinase protein performance as ALS biomarkers
               Alexander Thompson, Oxford 2861

               Imaging of brain metabolism in asymptomatic C9orf72 repeat
               expansion carriers and non-carriers using 31P-MRSI at 7T
               Henk-Jan Westeneng, Utrecht 3022

               Non-coding RNA serum biomarkers in ALS
               Greig Joilin, Sussex 2856

               Electric shock and extremely low-frequency magnetic field exposure
               and risk of ALS: Euro-MOTOR
               Susan Peters, Utrecht 2898

15.30-16.00   BREAK
16.00-16.30   How many DNA samples is enough?
               Michael van Es, Utrecht
16.30-18.00   Oligogenic and discordant inheritance: A population based genomic
               study of Irish kindreds carrying the C9orf72 repeat expansion
               Marie Ryan, Dublin 3011

               Next Generation Sequence Analysis of Telomere Length in ALS
Ahmad Al Khleifat, London (King’s) 3056

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
Kevin Kenna, Dublin 3055

Modelling FUS-amyotrophic lateral sclerosis using gene-edited isogenic iPSC reporter lines
Lara Marrone, Dresden 2756

Exogenous recombinant FUS is able to accumulate in cortical neurons in mouse brain
Mattia Perez, Strasbourg 2866

Superoxide dismutase prions transmit ALS disease in mice expressing hemizygous D90A hSOD1
Elaheh Ekhtiari Bidhendi, Umea 3053

1800.19.30 POSTERS
THURSDAY 21ST JUNE

0900.09.30  Reversing aberrant phase transitions connected to ALS
James Shorter, Philadelphia (U Penn)

09.30-10.30  Studying the interaction between TARDBP and p62/SQSTM1: a look into RNA processing defects in ALS
Raphael Munoz-Ruiz, Paris (ICM)  2934

Endogenous TDP-43 mutant mice develop ALS characteristics in vivo and show novel gain of splicing function
Pietro Fratta, London (UCL)  2908

FUS-induced neurotoxicity in drosophila is prevented by downregulating nucleocytoplasmic transport proteins
Jolien Steyaert, Leuven  2858

Structural and functional MRI reveals frontal cortical deficits in a TDP-43 knock-in mouse model of ALS-FTD
Ziqiang Lin, London (King’s)  2919

10.30-11.00  BREAK

11.00-11.30  Neuropathological heterogeneity across the ALS spectrum
Olaf Ansorge, Oxford

11.30-12.30  Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis
Christopher Henstridge, Edinburgh  2944

The anterior cingulate cortex in the ALS-FTD spectrum: post mortem MRI-histology correlation
Anna Leonte, Oxford  2947

Selective vulnerability of the primary motor cortex in amyotrophic lateral sclerosis
Matthew Nolan, Oxford  2885

Investigation of dysfunction in cognitive brain networks in ALS by localisation of the sources of mismatch negativity
Roisin McMackin, Dublin  3046

12.30-13.30  LUNCH
Axonal mRNA biology: implications for axonal maintenance
Christine Holt, Cambridge

HDAC6 inhibition reverses axonal transport defects in iPSC-derived motor neurons from FUS-ALS patients
Wenting Guo, Leuven 2879

Serum microRNA profiles identify the Fragile-X-protein family as novel neuropathological markers in ALS
Axel Freischmidt, Ulm 2801

C9ORF72 repeat expansions cause axonal transport defects in iPSC-derived motor neurons
Laura Fumagalli, Leuven 3017

Axon-seq decodes the motor axon transcriptome and its modulation in response to amyotrophic lateral sclerosis
Jik Nijssen, Stockholm 2793

MicroRNAs secreted by C9orf72 patient-derived astrocytes contribute to impairment in axonal growth and cell death in vitro
Andrea Varcianna, Sheffield 2962

Directly converted Astrocytes from ALS patient fibroblasts stratify Disease phenotypes and identify miR-146a as a potential therapeutic target
Cajitia Gomes, Lisbon 2912

Transcriptomic analysis of iPSC-derived motor neurons from C9orf72 ALS/FTD patients
Ana Candalija, Oxford 3051

Synergistic mechanisms of C9orf72 gain and loss of function
Hortense de Calbiac, Paris (ICM) 2948

Pur-alpha provides a potential link between RNA toxicity and loss-of-function in C9orf72 ALS
Bart Swinnen, Leuven 2883

Inosine supplementation bypasses adenosine deaminase deficiency in C9orf72 astrocytes increasing bioenergetic capacity and motor neurone survival
Scott Allen, Sheffield 2893
17.00-17.45 The ENCALS debate: This house believes ALS is a prion-like disease

FOR: Magdalini Polymenidou, Zurich (15 minutes)

AGAINST: Jon Rohrer, London (UCL) (15 minutes)

DISCUSSION (15 minutes)

17.45.19.15 POSTERS

20.00 CONFERENCE DINNER, KEBLE COLLEGE
FRIDAY 22ND JUNE

09.00-9.30  ENCALS Awards

09.30-10.00  Prospects for genetic therapies in neurodegenerative disorders  
Matthew Wood, Oxford

10.00-10.30  Clinical trials in ALS: stratification and personalised therapeutics  
Angela Genge, Montreal

10.30-11.00  BREAK

11.00-12.30  Implementing evidence-based methods in amyotrophic lateral sclerosis clinical trials  
Ruben van Eijk, Utrecht  2979

  Optimization of Preclinical Nucleic Acid based Therapeutic for the Most Common Genetic Form of Amyotrophic Lateral Sclerosis  
Helene Tran, Massachusetts (U Massachusetts)  2945

  WVE-3972-01, an Investigational Stereopure Antisense Oligonucleotide, Preferentially Knocks Down G4C2 Repeat-Containing C9ORF72 Transcripts  
Jean-Cosme Dodart, Massachusetts (WAVE Lifesciences)  2929

  G-quadruplex-binding small molecules ameliorate C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia pathology in iPSC neurons and in vivo  
Rubika Balendra, London (UCL)  3041

  AAV vectors for ALS treatment and modelling  
Maria Grazia Biferi, Paris (IM)  3062

  Randomized Phase 2B trial of NP001, a Novel Immune Regulator, in ALS  
Jonathan Katz, San Francisco  2977

12.30-12.45  INTRODUCTION TO ENCALS 2019 AND CLOSE OF MEETING